Delivery Order SPE2DB20D2104-SPE2DB25FMZCH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $34,200.83 under a firm fixed price contract type. The order was competitively awarded without set-aside designations and is scheduled for completion by August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery...
- The Defense Logistics Agency (DLA) awarded a $16,338.29 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors under a firm fixed-price contract type. This award, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a non-competitive delivery against an existing indefinite delivery contract. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $11,697.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a pediatric or maintenance supply delivery under DLA's medical procurement operations. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at approximately $42,601.58 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion on June 20, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZCHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a contract ceiling value of $9,937.75 under firm fixed pricing. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen Drug Corp's comprehensive IDC with the DLA valued at $999,999,999.00 through December 2026, which serves as a global pharmaceutical support vehicle supplying military healthcare systems. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen has demonstrated extensive capability in meeting federal medical procurement requirements, with a portfolio encompassing specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains for military and veteran healthcare systems. The Dupixent supply supports DLA's mission to provision pharmaceutical products for the Defense Health Agency and broader military medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 8/28/25 |